Live Analyst Rating Changes 23582 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Andy Hsieh
WB

Andy Hsieh

William Blair
Wall Street Analyst
★★☆☆☆
#2420
on 13Foresight · ranked by our own returns
49%
Success Rate
-1.5%
Average Return
22 of 45 calls profitable · -5.2% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 49% of Andy Hsieh's ratings turned a profit when each position was held for 1 year — averaging -1.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

102 Buy 44 Hold 0 Sell
Andy's Stock Coverage 21 ratings · 2026-08-12
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
CRDF
Cardiff Oncology
 Aug 11, 2026 HOLD Buy
+867.7% avg upside
18 analysts
 — · ·
LNTH
Lantheus
 Aug 08, 2026 HOLD Buy
-18.2% avg upside
21 analysts
 — -0.4% ·
GPCR
Structure Therapeutics, Inc. Sponsored ADR
 Aug 07, 2026 BUY Strong Buy
+98.6% avg upside
17 analysts
 — +1.3% ·
EXEL
Exelixis
 Aug 06, 2026 BUY Buy
-15.5% avg upside
34 analysts
 — -3.5% ·
BIOA
BioAge Labs, Inc.
 Aug 06, 2026 HOLD Strong Buy
+228.9% avg upside
9 analysts
 — -7.0% ·
CRBP
Corbus Pharmaceuticals
 Aug 06, 2026 BUY Strong Buy
+277.6% avg upside
20 analysts
 — +4.4% ·
VKTX
Viking Therapeutics
 Jul 30, 2026 BUY Strong Buy
+111.4% avg upside
31 analysts
 — +2.9% ·
TNYA
Tenaya Therapeutics
 Jul 29, 2026 BUY Strong Buy
+1235.0% avg upside
11 analysts
 — +2.0% ·
AVIR
Atea Pharmaceuticals
 Jul 28, 2026 BUY Buy
+29.1% avg upside
6 analysts
 — +12.5% ·
ALT
Altimmune
 Jul 28, 2026 HOLD Strong Buy
+793.0% avg upside
20 analysts
 — +3.0% ·
KLRA
Kailera Therapeutics, Inc.
 Jul 07, 2026 BUY Strong Buy
+138.5% avg upside
5 analysts
 — -16.1% ·
PYXS
Pyxis Oncology
 Jun 30, 2026 HOLD Strong Buy
+159.7% avg upside
14 analysts
 — +23.9% ·
AARD
Aardvark Therapeutics, Inc.
 May 15, 2026 BUY Buy
+145.7% avg upside
12 analysts
 — +72.9% ·
SKYE
Skye Bioscience
 May 12, 2026 BUY Strong Buy
+1827.0% avg upside
9 analysts
 — -32.1% ·
KYNB
Kyntra Bio
 May 12, 2026 HOLD Buy
+350.7% avg upside
15 analysts
 — -3.4% ·
NKTR
Nektar Therapeutics
 May 07, 2026 BUY Buy
-0.4% avg upside
26 analysts
 — -8.8% ·
ZLDPF
Zealand Pharma
 Mar 06, 2026 HOLD Buy
+61.0% avg upside
11 analysts
 — +19.4% ·
BRNS
Barinthus Biotherapeutics
 Aug 07, 2025 BUY Strong Buy
+602.9% avg upside
5 analysts
 — -58.7% ·
ATNM
Actinium Pharmaceuticals
 Dec 22, 2023 HOLD Strong Buy
+854.2% avg upside
11 analysts
 — -75.7% ·
BYSI
Beyondspring
 Dec 01, 2021 HOLD Hold
+921.5% avg upside
8 analysts
 — -88.4% ·
GILD
Gilead Sciences
 Feb 12, 2019 BUY Strong Buy
-12.1% avg upside
66 analysts
 — +6.3% ·
🔒 16 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Andy Hsieh — Frequently Asked Questions
How accurate are Andy Hsieh's stock ratings?
Based on the calls 13Foresight could measure, about 50% of Andy's ratings were profitable over a one-year hold, with an average return of -1.4% per rating, or -5.3% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Andy ranked on 13Foresight?
Andy Hsieh is currently ranked #2420 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Andy cover?
Andy most recently has ratings on CRDF, LNTH, GPCR, EXEL, BIOA, CRBP, VKTX, TNYA, AVIR, ALT, KLRA, PYXS and 9 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.